# Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

> **NCT05896930** · PHASE2 · COMPLETED · sponsor: **TASK Applied Science** · enrollment: 134 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Meropenem 6g IV over 6 hours
- **DRUG:** Ertapenem 1g IM
- **DRUG:** Meropenem 3g IV
- **DRUG:** Ertapenem 1g IV
- **DRUG:** Amoxicillin/CA twice daily
- **DRUG:** Rifampicin 35 mg/kg
- **DRUG:** Meropenem 6g IV over 60 minutes
- **DRUG:** Rifafour e-275
- **DRUG:** Meropenem 4g IV
- **DRUG:** Amoxicillin/CA once daily

## Key facts

- **NCT ID:** NCT05896930
- **Lead sponsor:** TASK Applied Science
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-09
- **Primary completion:** 2021-01-04
- **Final completion:** 2021-01-04
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896930, "Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05896930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*